




DOCKET NO.: W0571.70010US02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tuschl et al.
Serial No.: 09/821,832
Confirmation No.: 6240
Filed: March 30, 2001
For: RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA
INTERFERENCE
Examiner: Louis V. Wollenberger
Art Unit: 1635

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 16th day of November, 2006.


Sharon Lloyd

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 09/821,832
Conf. No.: 6240


- 3 -

Art Unit: 1635

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.


An early and favorable action is hereby requested.

Respectfully submitted,

By: 
Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: W0571.70010US02
Date: November 6, 2006
xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 09/821,832	ATTY. DOCKET NO.: W0571.70010US02	
		FILING DATE: March 30, 2001	CONFIRMATION NO.: 6240	
		APPLICANT: Tuschl et al.		
		GROUP ART UNIT: 1635	EXAMINER: Louis V. Wollenberger	
Sheet	of	5		



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,208,149		Inouye et al.	05-04-1993
		5,457,189		Crooke et al.	10-10-1995
		5,576,208		Monia et al.	11-19-1996
		5,594,122		Friesen	01-14-1997
		5,624,803		Noonberg et al.	04-29-1997
		5,898,031		Crooke et al.	04-27-1999
		5,998,203		Matulic-Adamic et al.	12-07-1999
		6,057,153		George et al.	05-02-2000
		6,476,205		Buhr et al.	11-05-2002
		6,635,805		Baulcombe et al.	10-21-2003
		6,939,712		Bahramian et al.	09-06-2005
		7,056,704		Tuschl et al.	06-06-2006
		7,078,196		Tuschl et al.	07-18-2006
		2002-0162126		Beach et al.	10-31-2002
		2003-0051263		Fire et al.	03-13-2003
		2003-0055020		Fire et al.	03-20-2003
		2003-0056235		Fire et al.	03-20-2003
		2003-0064945		Akhtar et al.	04-03-2003
		2003-0084471		Beach et al.	05-01-2003
		2003-0180756		Shi et al.	09-25-2003
		2004-0018999		Beach et al.	01-29-2004
		2004-0086884		Beach et al.	05-06-2004
		2004-0229266		Tuschl et al.	11-18-2004
		2004-0259248		Tuschl et al.	12-23-2004
		2005-0026278		Tuschl et al.	02-03-2005
		2005-0282764		Bahramian et al.	12-22-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 649 467	B1	Hybridon, Inc.	09-16-1998	
		EP	1 352 061	B1	Alnylam Europe AG	05-31-2006	Y-Abstract

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/821,832		ATTY. DOCKET NO.: W0571.70010US02	
				FILING DATE: March 30, 2001		CONFIRMATION NO.: 6240	
				APPLICANT: Tuschl et al.			
				GROUP ART UNIT: 1635		EXAMINER: Louis V. Wollenberger	
Sheet	2	of	5				

		GB	2 349 885	A	Devgen NV	11-15-2001	
		GB	2 362 885	A	Devgen NV	12-05-2001	
		GB	2 353 282	B	Benitec Australia Ltd.	04-06-2003	
		GB	2 370 275	A	Devgen NV	06-26-2002	
		WO	94/21767	A1	The Procter & Gamble Company	09-29-1994	
		WO	98/53083	A1	Zeneca Limited	11-26-1998	
		WO	99/14226	A2	Exiqon A/S	03-25-1999	
		WO	00/31271	A1	Hisamitsu Pharmaceutical Co., Inc.	06-02-2000	Y-Abstract
		WO	02/061034	A2	Invitrogen Corporation	08-08-2002	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		ALEXEEV et al., Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. Nat Biotechnol. 2000 Jan;18(1):43-7.	
		ALI et al., Who discovered (or invented 'the art' of double-stranded) RNA interference? Letter of Ali. May 6, 2005.	
		AMBROS et al., microRNAs: tiny regulators with great potential. Cell. 2001 Dec 28;107(7):823-6.	
		BARTEL et al., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23;116(2):281-97.	
		BARTEL et al., Micromanagers of gene expression: the potentially widespread influence of matazoan microRNAs. 2004; 5:369-400.	
		BAULCOMBE et al., Gene silencing: RNA makes RNA makes no protein. Curr Biol. 1999 Aug 26;9(16):R599-601.	
		BELLON et al., 4'-Thio-oligo-beta-D-ribonucleotides: synthesis of beta-4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase. Nucleic Acids Res. 1993 Apr 11;21(7):1587-93.	
		BRUMMELKAMP et al., New tools for functional mammalian cancer genetics. Nat Rev Cancer. 2003 Oct;3(10):781-9.	
		CAMERON et al., Inhibition of gene expression by a short sense fragment. Nucleic Acids Res. 1991 Feb 11;19(3):469-75.	
		CARRINGTON et al., Role of microRNAs in plant and animal development. Science. 2003 Jul 18;301(5631):336-8.	
		CARTHEW et al., Gene silencing by double-stranded RNA. Curr Opin Cell Biol. 2001 Apr;13(2):244-8.	
		CHECK et al., Gene regulation: RNA to the rescue? Nature. 2003 Sep 4;425(6953):10-2.	
		CHENG et al., RNA interference and human disease. Mol Genet Metab. 2003 Sep-Oct;80(1-2):121-8.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/821,832	ATTY. DOCKET NO.: W0571.70010US02
				FILING DATE: March 30, 2001	CONFIRMATION NO.: 6240
				APPLICANT: Tuschl et al.	
				GROUP ART UNIT: 1635	EXAMINER: Louis V. Wollenberger
Sheet	3	of	5		

	COUZIN et al., Molecular biology. RNAi shows cracks in its armor. Science. 2004 Nov 12;306(5699):1124-5.	
	CROOKE et al., Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J. 1995 Dec 1;312 (Pt 2):599-608.	
	CUMMINS et al., Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res. 1995 Jun 11;23(11):2019-24.	
	DE MESMAEKER et al., Backbone modifications in oligonucleotides and peptide nucleic acid systems. Curr Opin Struct Biol. 1995 Jun;5(3):343-55.	
	DEVROE et al., Therapeutic potential of retroviral RNAi vectors. Expert Opin Biol Ther. 2004 Mar;4(3):319-27.	
	ETEMAD-MOGHADAM et al., Asymmetrically distributed PAR-3 protein contributes to cell polarity and spindle alignment in early C. elegans embryos. Cell. 1995 Dec 1;83(5):743-52.	
	FILIPOWICZ et al., RNAi: the nuts and bolts of the RISC machine. Cell. 2005 Jul 15;122(1):17-20.	
	FLINTOFT et al., Virus alert. Nature Reviews Drug Discovery. 2003;2:512.	
	FREITAG et al., Controlling DNA methylation: many roads to one modification. Curr Opin Genet Dev. 2005 Apr;15(2):191-9.	
	GITLIN et al., Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol. 2003 Jul;77(13):7159-65.	
	GREENWOOD et al., Ever-decreasing effects. Nature Reviews Cancer. 2003;3:236.	
	HEINRICHS et al., Down a hairpin. Nature Reviews Molecular Cell Biology. 2003;4:173.	
	HEINRICHS et al., Spreading silence. Nature Reviews Molecular Cell Biology. 2003;4:823.	
	HEINRICHS et al., Chop, chop. Nature Reviews Molecular Cell Biology. 2003;4:829.	
	HUNTER et al., Genetics: a touch of elegance with RNAi. Curr Biol. 1999 Jun 17;9(12):R440-2.	
	HUNTER et al., Missing LINKS: miRNAs and plant development. Current Opinion in Genetics & Development. 2002;13:372-8.	
	HUTVAGNER et al., RNAi: nature abhors a double-strand. Curr Opin Genet Dev. 2002 Apr;12(2):225-32.	
	KETTING et al., Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 2001 Oct 15;15(20):2654-9.	
	KIDNER et al., Macro effects of microRNAs in plants. Trends Genet. 2003 Jan;19(1):13-6.	
	LAU et al., An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001 Oct 26;294(5543):858-62.	
	LIMA et al., Cleavage of single strand RNA adjacent to RNA-DNA duplex regions by Escherichia coli RNase H1. J Biol Chem. 1997 Oct 31;272(44):27513-6.	
	LIMA et al., The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J Biol Chem. 1997 Jul 18;272(29):18191-9.	
	LIN et al., RNA interference. Policing rogue genes. Nature. 1999 Nov 11;402(6758):128-9.	
	LIPARDI et al., RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell. 2001 Nov 2;107(3):297-307.	
	MAINE et al., A conserved mechanism for post-transcriptional gene silencing. Genome Biology. 2000;1(3):1018.1-1018.4.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/821,832		ATTY. DOCKET NO.: W0571.70010US02	
				FILING DATE: March 30, 2001		CONFIRMATION NO.: 6240	
				APPLICANT: Tuschl et al.			
				GROUP ART UNIT: 1635		EXAMINER: Louis V. Wollenberger	
Sheet	4	of	5				

	MALLORY et al., MicroRNAs: something important between the genes. Curr Opin Plant Biol. 2004 Apr;7(2):120-5.	
	MATHEWS et al., Adenovirus virus-associated RNA and translation control. J Virol. 1991;6(11):5657-62.	
	MATZKE et al., RNAi extends its reach. Science. 2003 Aug 22;301(5636):1060-1.	
	MATZKE et al., RNA-based silencing strategies in plants. Curr Opin Genet Dev. 2001 Apr;11(2):221-7.	
	MATZKE et al., RNAi-mediated pathways in the nucleus. Nat Rev Genet. 2005 Jan;6(1):24-35.	
	MELLO et al., Revealing the world of RNA interference. Nature. 2004 Sep 16;431(7006):338-42.	
	MONIA et al., Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993 Jul 5;268(19):14514-22.	
	MONIA et al., Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem. 1992 Oct 5;267(28):19954-62.	
	MONIA et al., Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15481-4.	
	MONTGOMERY et al., RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15502-7.	
	MOSS et al., MicroRNAs: something new under the sun. Current Biology. 2002;12:R688-90.	
	NOVINA et al., The RNAi revolution. Nature. 2004 Jul 8;430(6996):161-4.	
	NYKANEN et al., ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell. 2001 Nov 2;107(3):309-21.	
	PARRISH et al., Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell. 2000 Nov;6(5):1077-87.	
	RAZIN et al., CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J. 1998 Sep 1;17(17):4905-8.	
	ROSSI et al., RNAi and the P-body connection. Nat Cell Biol. 2005 Jul;7(7):643-4.	
	SCHRAMKE et al., Those interfering little RNAs! Silencing and eliminating chromatin. Curr Opin Genet Dev. 2004 Apr;14(2):174-80.	
	SCHWARTZ et al., Why do miRNAs live in the miRNP? Genes Dev. 2002 May 1;16(9):1025-31.	
	SIOMI et al., RNA interference: a new mechanism by which FMRP acts in the normal brain? What can Drosophila teach us? Ment Retard Dev Disabil Res Rev. 2004;10(1):68-74.	
	SIOUD et al., Therapeutic siRNAs. Trends Pharmacol Sci. 2004 Jan;25(1):22-8.	
	SKIPPER et al., Elegant tour de force. Nature Reviews Genetics. 2003;4:79-80.	
	SKIPPER et al., Have our dreams been shattered? Nature Reviews Genetics. 2003;4:671.	
	SMYTH et al., Gene silencing: cosuppression at a distance. Curr Biol. 1997 Dec 1;7(12):R793-5.	
	SONTHEIMER et al., Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol. 2005 Feb;6(2):127-38.	
	TIJSTERMAN et al., The genetics of RNA silencing. Annu Rev Genet. 2002;36:489-519.	
	TIMMONS et al., Specific interference by ingested dsRNA. Nature. 1998 Oct 29;395(6705):854.	
	TUSCHL et al., Functional genomics: RNA sets the standard. Nature. 2003 Jan 16;421(6920):220-1.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/821,832	ATTY. DOCKET NO.: W0571.70010US02
				FILING DATE: March 30, 2001	CONFIRMATION NO.: 6240
				APPLICANT: Tuschl et al.	
				GROUP ART UNIT: 1635	EXAMINER: Louis V. Wollenberger
Sheet	5	of	5		

		TUSCHL et al., RNA silencing: products and perspectives advancing cell discovery. Upstate Biosignals. 2003;3.	
		VAUCHERET et al., Transgene-induced gene silencing in plants. Plant J. 1998 Dec;16(6):651-9.	
		WANG et al., Replicating satellite RNA induces sequence-specific DNA methylation and truncated transcripts in plants. RNA. 2001 Jan;7(1):16-28.	
		WATERHOUSE et al., Exploring plant genomes by RNA-induced gene silencing. Nature Reviews Genetics. 2002;4:29-38.	
		WHALEN et al., DNA-mediated immunization to the hepatitis B surface antigen. DNA Vaccines: A new era in vaccinology. 1995:64-76.	
		WOO et al., G/C-modified oligodeoxynucleotides with selective complementarity: synthesis and hybridization properties. Nucleic Acids Res. 1996 Jul 1;24(13):2470-5.	
		WU et al., Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J Biol Chem. 2000 Nov 24;275(47):36957-65.	
		WU et al., Properties of cloned and expressed human RNase H1. J Biol Chem. 1999 Oct 1;274(40):28270-8.	
		YANG et al., Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi in Drosophila embryos. Curr Biol. 2000 Oct 5;10(19):1191-200.	
		ZAMORE et al., RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000 Mar 31;101(1):25-33.	
		ZAMORE et al., RNA interference: listening to the sound of silence. Nat Struct Biol. 2001 Sep;8(9):746-50.	
		ZAMORE et al., Ribo-gnome: the big world of small RNAs. Science. 2005 Sep 2;309(5740):1519-24.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.